The expression of fibroblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely define the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a significant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1a, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays confirmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These findings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system, implicate the angiopoietins as downstream effectors of FGFR1 activation in vivo, and suggest that therapies targeting FGFR1 could be used to inhibit neovascularization during initiation and progression of CaP.
The expression of fibroblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely define the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a significant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1a, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays confirmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These findings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system,Introduction A common feature of neoplasia is angiogenesis, the process by which solid tumors recruit new vasculature to grow beyond a few cubic millimeters in size (Folkman, 1971) . Hence, the activation of an 'angiogenic switch' must be an early event during tumorigenesis to sustain tumor growth (Folkman and Hanahan, 1991) . Elucidating the molecular mechanisms governing the angiogenic switch in various solid tissue tumors should facilitate the identification of both general and tissue-specific targets for improved antiangiogenic therapy.
A number of molecular pathways causally associated with the angiogenic switch have been identified. These include the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) pathways, as well as angiopoietinTie, Notch-Delta and ephrin signaling (Bicknell and Harris, 2004) . Of these, FGF signals are some of the most potent stimulators of angiogenesis and can promote the proliferation, migration, differentiation and tubulogenesis of endothelial cells in culture (Javerzat et al., 2002) . The FGF1 and FGF2 ligands were among the first identified angiogenic factors (Folkman and Shing, 1992; Bikfalvi et al., 1997) . Although they act primarily through FGF receptor 1 (FGFR1), lower levels of FGFR2 have also been detected in the vasculature (Nakamura et al., 2001) .
In addition to modulating angiogenesis through the vascular endothelium, FGF signaling pathways also play prominent roles in prostate biology by mediating stromal-epithelial interactions. In the normal prostate gland, the epithelium predominantly expresses the FGFR2-IIIb isoform that is activated by stromalderived cognate ligands FGF7 and FGF10 (Thomson, 2001) . Additionally, the epithelium expresses the FGF9 ligand that preferentially acts on a stromal-specific FGFR3 (Jin et al., 2004) . It is a generally held view that such reciprocal stromal-epithelial signaling pathways act to maintain the microenvironment and homeostasis of a terminally differentiated quiescent epithelium. So it is notable that several changes in the FGF signaling axis have been described in prostate cancer (CaP) that can disrupt normal stromal-epithelial interactions (Kwabi-Addo et al., 2004) . One such event is alternative mRNA splicing that generates the FGFR2IIIc isoform, which preferentially recognizes epithelial-derived FGF1, FGF2, FGF6 as well as FGF8, which is preferentially expressed in malignant prostate epithelium (Gnanapragasam et al., 2003) . Alternate splicing of FGFRs and differential expression of FGF ligands can impart stromal independence on the epithelium by establishing autocrine growth factorsignaling loops. Clinically, increased expression of FGF1 has been observed in regions of prostatic intraepithelial neoplasia (PIN) and CaP (Dorkin et al., 1999) . Moreover, expression of FGF2 in stromal cells has been shown to be approximately 2.5-fold higher in clinically localized CaP compared to normal prostate (Giri et al., 1999) , and epithelial expression of FGF2 has been detected in advanced CaP (Dorkin et al., 1999) . This upregulation of FGF2 during CaP progression has been clinically correlated with angiogenesis (Doll et al., 2001) . In addition, FGFR1 is also preferentially expressed in advanced clinical CaP (Giri et al., 1999) .
CaP is the most commonly diagnosed malignancy and the third leading cause of cancer-related deaths among men in the United States, with approximately 234 000 new cases and 27 000 deaths anticipated for 2006 (American Cancer Society, 2006) . Given the extremely heterogeneous nature of the disease, it is likely that the development of efficacious prevention and intervention strategies will require thorough understanding of the molecular pathways that control and modulate initiation and progression events. Owing to the difficulty in studying the consequences of specific molecular events using heterogeneous clinical samples, we and others have employed inbred genetically engineered mouse (GEM) models to further investigate the role of FGF signaling in CaP initiation and progression. The GEM models are advantageous since they have the ability to recapitulate many spontaneous and stochastic changes during the initiation, progression, metastasis and emergence of androgen ablation-resistant CaP (Winter et al., 2003) . These models are particularly well suited to the examination of the earliest events during tumor progression, such as angiogenesis, and have proven their utility in examining the effects of specific pathway alterations in vivo. Although the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model (Greenberg et al., 1995) recapitulates many of the changes in the FGF axis observed clinically, such as exhibiting higher expression of FGFR1 in advanced tumors and in portions of tumor vasculature (Huss et al., 2003) , and increased expression of both FGF1 (Foster et al., 1999) and FGF2 (Huss et al., 2003) during tumor progression, the TRAMP model does not allow specific regulation of FGFR1. Therefore, to better define the role of FGFR1 in the prostate, mice were generated that express a constitutively active FGFR1 (caFGFR1) under the control of the probasin promoter. These mice will exhibit FGFR1-dependent progressive hyperplasia and PIN . Unfortunately, the probasin promoter only becomes active at sexual maturity, typically around 4 weeks of age (Greenberg et al., 1994) . Hence, the caFGFR1 model is not ideal for studying the regulation of FGFR1 activity as a function of time. To investigate more precisely the consequence of temporally activated FGFR1 signaling in the prostate epithelium, a conditional system was established wherein activation of the receptor is dependent on a synthetic compound called the 'chemical inducer of dimerization' (CID). Using the prostate-specific ARR 2 PB promoter (Zhang et al., 2000) , mice have been generated that express a CID-regulated FGFR1 (Freeman et al., 2003) . These mice, termed the 'Juxtaposition of CID and Kinase-1' (JOCK-1) model, exhibit profound epithelial hyperplasia when CID is administered for 1 month. The hyperplastic phenotype is dependent on CID, as withdrawal of CID causes regression of the epithelial compartment. High-grade PIN with thickened stroma and evidence of nuclear atypia are typically observed in JOCK-1 mice after 6 months (Freeman et al., 2003) . Following longer periods of CID treatment (>40 weeks), mice ultimately develop CID-independent adenocarcinoma with foci of both well-differentiated and poorly differentiated lesions (V Acevedo, E Nikitina, M. Ittmann and D. Spencer; unpublished observations). Hence, the JOCK-1 model represents a novel system with which to test the causal association between epithelial FGFR1 activation, angiogenesis and CaP progression.
Here, we report development of a novel method for high-resolution volumetric quantitation of vasculature in three dimensions and demonstrate rapid induction of angiogenesis following inducible FGFR1 (iFGFR1) dimerization in JOCK-1 mice. Although it was predicted that new vasculature would remain dependent on iFGFR1 activation, remarkably, the elevated vessel density persisted despite the withdrawal of CID, implying that iFGFR1 in the epithelial compartment initiated stable changes in the vascular space that allowed the neovasculature to persist. To identify the angiogenic events that were differentially regulated as a result of iFGFR1 activation, we paid particular attention to secreted factors that might mediate a proangiogenic signal between the epithelium and the preexisting vascular network in the stroma from which new vessels would be recruited. Consistent with expectations, we observed upregulation of hypoxia-inducible factor 1a (HIF-1a) and its transcriptional target VEGF. However, we were surprised to find that angiopoietins 1 and 2 (Ang-1 and Ang-2) were also differentially expressed at both the mRNA and protein level in JOCK-1 mice in a CID-dependent fashion. Using luciferase reporter assays in vitro, we confirmed that the Ang-2 promoter was directly regulated by FGFR1 signaling. These results provide crucial insight regarding the proangiogenic role of FGFR1 in CaP, and establish a framework for developing and testing strategies to specifically target this axis for therapeutic effect.
Results
Quantitation of the angiogenic phenotype in JOCK-1 mice To examine the consequence of epithelial iFGFR1 activation with respect to angiogenesis in the prostate, cohorts of age-matched JOCK-1 littermates were administered AP20187 (CID) or a vehicle control solution for 1, 2, 4 or 6 weeks beginning at 12 weeks of age. To control for possible increases in vasculature accompanying normal prostate growth over the course of treatment, the reference cohort only received vehicle over the 12-week period such that their ages would match those of the oldest mice receiving CID.
As shown in Figure 1A , in vivo fluorescein isothiocyanate (FITC)-lectin labeling was used to identify blood vessels. In control mice (panel a) the vessels were few in number and surrounded the acini in a wellorganized network. Colabeling was performed with an Alexa Fluor 633-phalloidin conjugate to visualize tissue ultrastructure (example shown in panel a). After 1 week of iFGFR1 activation by CID (panel b), the vessels remained well ordered, and we only observed slight increases in the number and size of vessels. After 2, 4, and 6 weeks (panels c, d and e) of CID, we not only observed an increase in the number of vessels, but that they also acquired a more tortuous appearance.
Volumetric analysis of high-power fields ( Figure 1B ) revealed that the FITC-labeled vasculature accounted for an average of 8.2% of the total tissue volume in 24-week-old controls. Remarkably, a small but statistically significant (ANOVA, Po0.05) increase in vascular volume to 11.3% was observed after just 1 week of activated iFGFR1 signaling. The vascular volume continued to increase after 2 (15.2%) and 4 (17.2%) weeks of CID treatment, and reached a maximum level of 20.9% after 6 weeks of CID, a 2.5-fold increase compared to control mice. FGFR1-induced angiogenesis was probably maximal at 6 weeks because we were unable to determine any significant difference in vasculature between these mice and those given CID for up to 12 weeks (data not shown).
To investigate the reversibility of iFGFR1-induced angiogenesis, mice treated for 6 weeks with CID were aged an additional 6 weeks without CID before necropsy. As shown in Figure 1A (panel f), CID withdrawal appeared to cause very little change in the angiogenic phenotype. However, a statistically Figure 1 Angiogenesis in JOCK-1 mice labeled with FITC-lectin. (A) Thick 100 mm prostate sections were imaged by confocal microscopy. a, mouse administered vehicle for 12 weeks, with Alexa633-phalloidin counterstain shown in red; b, c, d, e, mice administered AP20187 (CID) for 1, 2, 4 and 6 weeks respectively; f, mouse given CID for 6 weeks and then vehicle for 6 weeks before sacrifice. For each mouse (n ¼ 3 per cohort) four high-power ( Â 400) fields of the highest vascular density from each of the dorsal (DP), lateral (LP) and ventral (VP) prostate lobes were quantitated with respect to vascular volume (B) and vessel branching (C). Statistics were calculated by ANOVA using Fisher's least significant difference. w, all times given in weeks; *Po0.05; **Po0.01 and ***Po0.001. Data are shown as the mean7standard error (s.e.) Scale bar ¼ 50 mm.
Conditional activation of FGFR1 in the prostate epithelium SF Winter et al significant decrease in vascular volume from 20.9 to 17.0% was observed 6 weeks after CID withdrawal ( Figure 1B) .
We next performed image analysis in three dimensions as this not only allows observation of individual vessel branch points but also facilitates a more accurate determination of vessel number by eliminating the possibility that a single tortuous vessel would be counted multiple times as might occur in thin section analysis. To determine the extent of vascular branching, we manually counted branch points, defined as the intersection of three distinct vessel segments. By this criterion, the areas of highest vascular density in control mice were found to contain an average of 9 branch points per field ( Figure 1C ). Although there was a slight upward trend to an average of 11 branch points per field following 1 week of iFGFR1 activation, this was not statistically significant. As shown in Figure 1C , branching increased rapidly, with 19 and 29 branch points per field detected after 2 and 4 weeks of iFGFR1 activation, respectively, and reached a maximum of approximately 30 branch points per field following 6 weeks of CID treatment. Withdrawal of CID for an additional 6 weeks did not cause any statistically significant change in vascular branching.
To validate our branch-point analysis as an accurate measure of changing vessel numbers during angiogenesis, we performed a microvessel density (MVD) analysis (Weidner et al., 1993) on thin frozen sections using an antibody to CD31/PECAM-1 (Figure 2a) . Vessels in the interductal stromal space (black arrows) were considered to be normal vasculature, and only those vessel segments that appeared to lie on or within the acinar boundary (red arrows) were included in the analysis. The MVD in control mice was 1 vessel per field. As shown in Figure 2b , the MVD was not significantly increased after 1 week of iFGFR1 activation, in agreement with our branch-point analysis. After 2 and 4 weeks of CID, the MVD increased significantly to 4 and 7 vessels per field, respectively, and reached a maximum of 14 vessels per Â 400 field after 6 weeks of enforced iFGFR1 signaling. Consistent with the branchpoint analysis, we were unable to determine a significant difference in MVD following 6 weeks of CID withdrawal. Collectively, these results demonstrate that while iFGFR1 activation in the prostate epithelium could rapidly induce angiogenesis, sustained iFGFR1 activation was not essential for the maintenance of newly established vasculature.
Identification of molecular pathways involved in FGFR1-mediated angiogenesis in vivo We postulated that activated iFGFR1 would cause new vasculature to be recruited to the proliferating prostatic epithelium, at least initially, from the preexisting vasculature in the stroma. Therefore, we sought to identify molecular signaling pathways differentially regulated in response to iFGFR1 activation in the epithelium that could mediate this response in vivo. As iFGFR1 activation is known to induce rapid epithelial proliferation (Freeman et al., 2003) , we first examined whether the hyperplastic phenotype would cause localized hypoxia and thereby result in a stabilization of HIF-1a (Wang and Semenza, 1995) with concomitant upregulation of VEGF signaling (Forsythe et al., 1996) . Here we chose to analyse prostate protein extracts from JOCK-1 mice treated with CID for 2 weeks because quantitative measurements of vasculature in the various cohorts suggested that angiogenesis was proceeding in a linear fashion between 2 and 4 weeks of enforced JOCK-1 mice were given AP20187 (CID) for 1, 2, 4 or 6 weeks. An additional cohort was given CID for 6 weeks and then vehicle for 6 weeks before necropsy. To control for any age-related effects on MVD, a cohort was given vehicle only for 12 weeks such that the age of the mice at sacrifice was the same as the age of the oldest CID treated mice. Frozen sections were stained with an antibody against CD31 (a) and microvessels lying within acinar perimeter (red arrows) were counted manually. Interductal vessels (black arrows) were considered normal and therefore not included. For each mouse (n ¼ 3 per cohort), four Â 200 fields of the highest vascular density were counted from each of the dorsal (DP), lateral (LP) and ventral (VP) prostate lobes, and statistics were calculated by ANOVA using Fisher's least significant difference. w, all times given in weeks; *Po0.05; **Po0.01 and ***Po0.001. Data are shown as the mean7s.e. iFGFR1 activation. As shown in Figure 3 , Western blots revealed a dramatic increase in HIF-1a protein in the prostate samples procured from mice given CID compared with those receiving vehicle. We also observed increased expression of VEGF, VEGF receptor-1 (VEGFR-1) and VEGFR-2 following iFGFR1 activation.
Using RNA isolated from total prostate extracts, we performed a quantitative real-time polymerase chain reaction (QRT-PCR) screen to observe the differential expression of endothelial cytokines Ang-1 and Ang-2 following iFGFR1 activation. Ang-1 mRNA was downregulated approximately two-fold, whereas Ang-2 expression had nearly doubled in mice given CID compared with those receiving only vehicle (Supplementary Figure S1 ). Interestingly, a similar shift in the Ang-2/ Ang-1 expression ratio favoring Ang-2 has been reported in expression profiles of a wide variety of solid tumors (Tait and Jones, 2004) , and has also been observed in clinical CaP specimens (Lind et al., 2005) . Therefore, we decided to further investigate the differential regulation of these angiopoietins by iFGFR1 signaling in vivo. To this end, we performed western blots to examine steady-state levels of Ang-1 and Ang-2 proteins, as well as their cognate receptor Tie-2 (Figure 3b ). Control mice were found to express uniformly low levels of Ang-1 protein that we detected as a single band with an apparent molecular weight of 55 kDa. We were unable to detect expression of Ang-1 protein in the prostates of mice receiving CID. Only the mature glycosylated form of Ang-2 (Kim et al., 2000) with a molecular weight of 70 kDa was detected in control mice. However, following iFGFR1 activation, we detected not only increased abundance of mature Ang-2, but also the expression of the 55 kDa form. Expression of the endothelial cell-specific Tie-2 receptor was also consistent with the increased vasculature following iFGFR1 induction.
Localization of Ang-1 and Ang-2 protein in JOCK-1 mice We performed immunohistochemistry to detect expression of Ang-1 and Ang-2 using prostate sections procured from mice receiving either CID or vehicle for 6 weeks. In controls, a majority of acini showed strong expression of Ang-1 (Figure 4 ) in a discontinuous peripheral pattern (panel a), indicating that Ang-1 was primarily expressed in basal epithelial cells. This was confirmed with an antibody to the basal epithelial marker keratin 5 (K5) (Hayward et al., 1996) (panel b) . In contrast, we noted that expression of Ang-1 in the basal compartment was almost completely lost after 6 weeks of CID treatment (panel c). We were able to detect K5 þ basal epithelium in the proliferative lesions (panel d). It is therefore unlikely that loss of Ang-1 expression was simply due to a loss of the basal epithelial subpopulation.
To better characterize the level of Ang-1 expression, sections from control and CID-treated mice were probed with an anti-Ang-1 antibody and labeling intensities were determined (panel e). In controls, the majority of acini (83%) showed strong Ang-1 expression and only a small fraction of acini (4%) showed no detectable Ang-1 expression. Conversely, in mice receiving CID for 6 weeks, 82% of acini had no detectable Ang-1 expression and only 3% of acini were strongly positive for Ang-1. Both the control and CID cohorts had similar numbers (13 and 15% respectively) of moderately positive acini.
In contrast to the results with respect to Ang-1, expression of Ang-2 ( Figure 5 ) in control tissue was uniformly low in the luminal epithelial compartment in controls (panel a and b) but significantly elevated after 6 weeks of iFGFR1 activation (panel c and d). These data suggest that the prostatic epithelial cells constitutively express low levels of Ang-2 in JOCK-1 mice, and the increased expression following CID-treatment was likely due to increased epithelial cell density as well as increased expression of Ang-2 on a per cell basis.
Induction of Ang-2 expression by FGFR1 signaling
To explore the possibility that the angiopoietins were transcriptionally regulated by FGFR1 signals, we exploited a TRAMP-C2N mouse prostate cell line stably transfected with the CID-inducible FGFR1. Here, cells were treated with CID or vehicle for 4 h and total RNA was prepared for QRT-PCR analysis with primers specific for Ang-1 or Ang-2. Although we were unable to observe a significant change in the Ang-1 expression level, we detected a significant 3.2-fold increase in Ang-2 expression (Supplementary Figure  S2) , suggesting that Ang-2 was likely a direct target of iFGFR1 signaling. Figure 3 Activation of FGFR1 signaling in the prostate epithelium-induced differential expression of angiogenesis-related proteins. JOCK-1 transgenic mice were given CID (n ¼ 3) or vehicle (n ¼ 2) for 2 weeks, and western blots were performed using total prostate protein extracts. b-Actin was used as a loading control and apparent molecular weights in kilodaltons (kDa) are indicated at left.
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To confirm the regulation of Ang-2 by FGFR1, a hemagglutinin (HA)-tagged full-length wild-type mouse FGFR1iiica isoform was first introduced by transient transfection into COS-7 cells. As shown in Figure 6 , expression of the HA-FGFR1 protein was confirmed using antibodies to both HA and FGFR1 (panel a). The HA-FGFR1 was tyrosine phosphorylated when cells were maintained in complete media (panel b), and we detected robust phosphorylation of Erk 1 and 2 when HA-FGFR1 transfected cells were treated with 10 ng/ml bFGF (panel c). We next cotransfected HA-FGFR1 with an Ang-2 luciferase reporter and determined that HA-FGFR1 could stimulate Ang-2 promoter activity 2.6-fold (2.670.4; Po0.02) in the presence of bFGF (panel e). Interestingly, in the absence of exogenous bFGF, expression of HA-FGFR1 alone caused a 1.7-fold (1.770.2; Po0.04) increase in Ang-2 promoter activity, which we attribute to residual receptor activity following serum starvation (panel d). To confirm that Ang-2 promoter activity was truly dependent on FGFR1 activity, cells expressing HA-FGFR1 were treated with PD173074, a specific inhibitor of FGF receptor activity (Mohammadi et al., 1998) . Treatment with PD173074 inhibited tyrosine phosphorylation of HA-FGFR1 independent of exogenous bFGF (panel d) and caused Ang-2 promoter activity to return to baseline levels (panel e). Collectively, these results demonstrate that the Ang-2 promoter was specifically activated by FGFR1.
Discussion
The increased expression of FGFR1 and bFGF has previously been correlated with angiogenesis during CaP progression (Giri et al., 1999; Doll et al., 2001) . Using the conditional and reversible JOCK-1 model system where FGFR1 activation in the prostate epithelium can be temporally regulated, we now demonstrate a direct causal relationship between activation of FGFR1 and an angiogenic switch.
Having established a method to examine angiogenesis quantitatively in three dimensions, we demonstrate that Figure 4 Ang-1 expression in basal epithelial cells was lost following AP20187 (CID) treatment of JOCK-1 mice. In miceadministered vehicle, the majority of prostate acini exhibited strong peripheral Ang-1 expression (a). Immunohistochemical analysis on serial sections with antibodies to Ang-1 (a) and the basal epithelial marker K5 (b) confirms that Ang-1 was expressed in basal epithelial cells in control mice. However, after 6 weeks of CID treatment, the majority of acini failed to express Ang-1 (c) despite the continued presence and proliferation of K5-positive basal epithelial cells (d). The percentage of acini with zero (0), moderate ( þ ) or strong ( þ þ ) Ang-1 reactivity was then determined for both vehicle control (VEH) and CID cohorts (e). Data are shown as the mean7s.d. Figure 5 Ang-2 expression was increased following induction of FGFR1 signaling by CID. Acini in control mice (a) exhibited low expression of Ang-2, and examination under Â 20 magnification (b and inset) revealed uniform expression at the apical surface of luminal epithelium as well as scattered stromal reactivity. Staining was not observed in sections incubated with a negative control IgG (a inset). In mice given CID for 6 weeks, acini stained more intensely for Ang-2 (c). Closer examination (d and inset) revealed that Ang-2 was expressed primarily in the luminal epithelium. The overall abundance of Ang-2 was increased owing to a combination of a proliferative expansion of the epithelial compartment that expressed Ang-2 uniformly, as well as an elevated per-cell intensity relative to control mice (compare d to b). a significant increase in vascular volume can follow just 1 week of iFGFR1 activation despite histologic evidence of only minimal hyperplasia. This supports our conclusion that angiogenesis is a primary response to the activation of FGFR1 in the epithelium. Interestingly, vascular branching and MVD analysis did not show a statistically significant increase in vasculature until at least 2 weeks of CID treatment, consistent with observations that vessel dilation can precede sprouting during the angiogenic switch (Bergers and Benjamin, 2003) . This underscores how our quantitative measurement of vascular volume in three dimensions allowed a more sensitive detection of the earliest stages of angiogenesis than more conventional two-dimensional MVD. Furthermore, assessment of vascular branching in three dimensions reduced the probability of a single tortuous vessel being counted multiple times.
It was curious that activation of iFGFR1 by CID induced such a rapid angiogenic response when subsequent withdrawal of CID for 6 weeks did not result in an equally rapid reversal of the phenotype. Although we observed a statistically significant decrease in vascular volume, no significant differences were detected by the vascular branching and MVD analyses. This suggests that an activated FGFR1 in the prostate epithelium was able to induce the formation of new vessels but continued activation of iFGFR1 was not strictly required for vessel maintenance. Our data imply that therapies designed to target the FGFR1 signaling axis would inhibit neovascular growth but would not likely cause established vasculature to regress.
In characterizing the molecular mediators contributing to the angiogenic phenotype as a consequence of iFGFR1 activation, we reasoned that the rapid induction of epithelial proliferation in the JOCK-1 model could lead to regions of localized hypoxia. Indeed, we were able to detect stabilization of HIF-1a and a concomitant upregulation of VEGF, VEGFR1 and VEGFR2. This was consistent with previous studies demonstrating that HIF-1a can be upregulated under normoxic conditions by PI3K and ERK signaling (Dery et al., 2005) , both of which are known to be activated by FGFR1 (Kwabi-Addo et al., 2004) . Clearly the upregulation of the VEGF signaling axis plays a significant role in the angiogenic phenotype as a consequence of iFGFR1 activation.
Our observations of the dramatic shift in steady-state mRNA encoding Ang-1 and Ang-2 to favor Ang-2 were consistent with previous reports examining a number of solid malignancies including colorectal, skin, ovarian and breast cancers (Tait and Jones, 2004) . We confirmed our mRNA expression data at the protein level by demonstrating the loss of Ang-1 and increase in both the 55-and 70-kDa forms of Ang-2. Because Ang-1 and Ang-2 are soluble factors that can act on the vasculature in a paracrine fashion, we examined the immunohistochemical Figure 6 Activation of the Ang-2 promoter by FGFR1. COS-7 cells growing in complete media were transiently transfected with an HA-tagged wild-type FGFR1, or pcDNA3.1 as a control. Western blots were performed to verify expression (a). HA-FGFR1 was immunoprecipitated using HA and FGFR1 antibodies and was tyrosine phosphorylated (b). After 24 h of serum starvation, stimulation with 20 ng/ml bFGF potently induced phosphorylation of downstream signaling targets Erk 1 and 2 in HA-FGFR1-transfected cells but not cells transfected with an empty vector (c). The phosphorylation of HA-FGFR1 was inhibited by PD173074 both in the absence or presence of exogenous bFGF (d). COS-7 cells were cotransfected with HA-FGFR1 (or pcDNA3.1 vector) and the pGL3-pAng-2 luciferase reporter (e). Following 24 h of serum starvation, cells were treated with bFGF (or PBS control solution) in the presence or absence of PD173074 (or DMSO control). Normalized luciferase data are shown as mean7s.e. and statistics were calculated using paired t-tests. *Po0.05 and **Po0.01. localization of these proteins. Concomitant with epithelial-specific iFGFR1 activation, we observed increased Ang-2 production by the luminal epithelium and a loss of Ang-1 expression in the basal epithelium.
Having established that activation of iFGFR1 in a prostate cell line could cause upregulation of Ang-2 mRNA, we examined activation of the Ang-2 promoter by wild-type FGFR1. We confirmed that our HAtagged FGFR1 was functional and, when cotransfected with an Ang-2-luciferase reporter, caused a 2.6-fold increase in Ang-2 promoter activity, consistent with our QRT-PCR, western blot and immunohistochemistry data. Treatment with PD173074 dramatically inhibited FGFR1 phosphorylation and blocked subsequent Ang-2 luciferase reporter activity, establishing that Ang-2 promoter activity was directly modulated by the activity of FGFR1.
Although we detected a consistent loss of Ang-1 expression in vivo, it remains unclear whether this was a cell-autonomous consequence of JOCK-1 transgene activation by CID. Indeed there are reports that transgenes driven by the ARR 2 PB promoter can be expressed in the basal epithelial compartment (Wang et al., 2006 ), but we were unable to detect localization of the HA-tagged JOCK-1 transgene in K5 þ basal cells using immunofluorescence, nor could we detect changes in expression of an Ang-1 reporter following activation of wild-type FGFR1 (data not shown). Therefore, we cannot presently conclude that FGFR1 directly represses Ang-1 expression, and it remains to be determined whether the loss of Ang-1 in the basal epithelium represents a cell-autonomous response to iFGFR1 activation or an indirect response to robust iFGFR1 activation in the adjacent luminal epithelium.
A loss of Ang-1 expression in the basal epithelium and increased Ang-2 expression in the luminal epithelium has been reported in clinical CaP specimens (Lind et al., 2005) , supporting the clinical relevance of our GEM system. We therefore propose that the Ang-1 produced in the basal epithelial cells exerts a stabilizing effect on the proximal periacinar vasculature and any disruption in homeostasis associated with CaP progression would favor Ang-2, thereby contributing to a state of vascular plasticity conducive to the formation of new vessels. Our data now show that this component of the angiogenic switch in the prostate can be activated specifically by FGFR1.
Materials and methods
Transgenic mice and reagents JOCK-1 transgenic mice were maintained in-house in an FVB/ N background as previously described (Freeman et al., 2003) . Mice were kept in a barrier facility under veterinary supervision in the Transgenic Mouse Facility at Baylor College of Medicine, Houston, TX, USA and at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Where appropriate, mice were administered 10 mg/kg AP20187 (Ariad Pharmaceuticals, Cambridge, MA, USA) twice per week via intraperitoneal injection in a sterile vehicle solution of 10% PEG-400, 1.5% Tween-80. Controls received vehicle alone. All experiments were conducted using the highest standards for humane care in accordance with the NIH Guide for the Care and Use of Laboratory Animals.
In vivo labeling and specimen collection Mice were anesthetized using Avertin (240 mg/kg) and immobilized. Vasculature was labeled by injecting 50 mg of FITC-conjugated Lycopersicon esculentum lectin (FL-1171; Vector Laboratories, Burlingame, CA, USA) into the left ventricle. Mice were then euthanized and perfused with a fixative containing 1% paraformaldehyde and 0.5% glutaraldehyde in phosphate-buffered saline (PBS), subsequently rinsed with PBS, and the urogenital tracts were removed. The dorsal, lateral and ventral lobes of the prostate were microdissected, flash frozen in OCT using a liquid nitrogen and isopentane bath, and stored at À801C.
Quantitation of vascular volume and branching
Frozen sections were cut to a thickness of 100 mm, then dried and post-fixed in 4% paraformaldehyde for 15 min at room temperature. After washing with PBS, sections were incubated with a 1:500 dilution of an AlexaFluor 633-phalloidin conjugate (A-22284; Molecular Probes, Eugene, OR, USA) to facilitate observation of the glandular ultrastructure. Slides were washed again in PBS and cover slipped using Vectashield (Vector Labs). High-power ( Â 400) fields were chosen using the hot-spot method (Weidner et al., 1991) and images were obtained using a Zeiss LSM 510 confocal laser-scanning microscope. If necessary the resulting data sets were cropped, based on the phalloidin label, such that regions lacking ducts would not negatively skew the volumetric data. Images were then analysed on a Sun Microsystems Onyx2 workstation using IRIS Explorer software (Numerical Algorithms Group, Oxford, UK). The number of voxels labeled with FITC-lectin was computed and expressed as a percentage of the total number of voxels in the image. Vascular branching data was obtained by manually counting vessel branch points in each image, using Zeiss AIM software to facilitate three-dimensional visualization. Four image sets were captured and analysed from each of the dorsal, lateral and ventral prostate lobes, for a total of 12 sections per mouse and each cohort had a minimum of three mice. Statistical analysis was performed by nonparametric ANOVA using Fisher's least significant difference.
RNA preparation
Total prostate RNA was prepared from a subset of mice not receiving the FITC-lectin labeling. The dorsal, lateral and ventral lobes were microdissected, incubated overnight at 41C in RNAlater (7020; Ambion, Austin, TX, USA), and stored at À801C. Total RNA was prepared using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to manufacturer's instructions.
Quantitative real-time RT-PCR cDNA was generated from total RNA using MMLV-RT (Invitrogen, Carlsbad, CA, USA). QRT-PCR was performed using using an iCycler system (Bio-Rad, Hercules, CA, USA) with a SYBR Green master mix (Bio-Rad) according to manufacturer's instructions. Polymerase chain reaction (PCR) amplification of each sample was performed using primers specific for the ribosomal gene S16 to allow for normalization of cDNA loading. Gene-specific oligonucleotides for Ang-1 (Zhang et al., 2003) , Ang-2 (Zhang et al., 2003) and S16 (Foley et al., 1993 ) were used as previously described. All samples were run in duplicate and single-band products were confirmed by electrophoresis through a 2% agarose/tris-borate-EDTA gel. Relative fold changes were calculated using the 2 -DDCt method (Livak and Schmittgen, 2001 ) and the 95% confidence intervals (CI) were determined by calculating the mean 7 two standard deviations.
Western blots
Prostate tissue (dorsal, lateral and ventral lobes) was homogenized and lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS)) containing protease inhibitor (11836170001, Roche, Mannheim, Germany) and phosphatase inhibitor (P5726, Sigma, St Louis, MO, USA) cocktails. SDS-PAGE was performed using standard methods. Membranes were incubated with primary antibodies, Ang-1 (1:250, #AB3120, Chemicon, Temecula, CA, USA), Ang-2 (1:250, #AB3121, Chemicon), Tie-2 (1:200, #SC-324, Santa Cruz Biotechnology, Santa Cruz, CA, USA), VEGF (1:500, #RB-222-P1, NeoMarkers, Fremont, CA, USA), Flt-1/ VEGFR1 (1:200, #SC-316, Santa Cruz), Flk-1/VEGFR2 (1:500, #SC-505, Santa Cruz), HIF-1a (1:500, #100-134, Novus, Littleton, CO, USA) or b-actin (1:2,000, #A5316, Sigma) overnight at 41C. Primary antibodies used in COS-7 transfection experiments included HA (1:500, #SC-805, Santa Cruz), FGFR1 (1:400, #F5421, Sigma), phosphotyrosine (1:1000, #610000, BD Biosciences, San Diego, CA, USA), phospho-p44/42 (1:1000, #9101, Cell Signaling Technologies, Beverly, MA, USA) and total p44/42 (1:1000, #9102, Cell Signaling). Membranes were washed several times with trisbuffered saline tween (TBST) and incubated with horseradish peroxidase-linked goat anti-rabbit (1:30,000, #170-6515, BioRad) or goat anti-mouse IgG (1:30,000, #170-6516, Bio-Rad) for 1 h at room temperature. Membranes were again washed several times and bands were visualized using SuperSignal chemiluminescence substrate (Pierce, Rockford, IL, USA) and BioMax XAR film (Kodak, Rochester, NY, USA).
Immunohistochemistry
Frozen sections were cut to a thickness of 10 mm, transferred to Superfrost Plus slides (StatLab, Lewisville, TX, USA) and stored at À801C until use. Sections were fixed in cold 100% acetone for 10 min, allowed to dry briefly, and washed in PBS. Alternatively, 5 mm paraffin sections were baked overnight on slides before storage. Paraffin sections were rehydrated through xylenes and graded alcohol, and antigen retrieval was performed by boiling in 10 mM sodium citrate, pH 6.0. Slides were blocked using Superblock (Pierce) plus 3% nonimmune serum from the species in which the secondary antibody was raised. Primary antibodies, Ang-1 (1:250, #AB3120, Chemicon), Ang-2 (1:250, #AB3121, Chemicon), K5 (1:500, #PRB-160P, Covance, Princeton, NJ, USA) or CD31/PECAM-1 (1:200, #550274, BD Biosciences), were diluted in blocking buffer and sections were incubated overnight at 41C. Slides were then washed several times in PBS and incubated in a 1:1000 dilution of biotinylated anti-rabbit or anti-rat secondary Ab (Vector) in PBS for 1 h at room temperature. Slides were washed in PBS and developed using the Vectastain ABC kit (Vector) according to manufacturer's instructions. Sections were counterstained in 0.1% methyl green, dehydrated through acetone and xylenes and coverslipped using Permount (Fisher Scientific, Pittsburgh, PA, USA).
Microvessel density
Sections labeled using the CD31 antibody were examined at Â 400 magnification. The number of microvessels was counted in four high-power fields of the dorsal, lateral and ventral prostate lobes for a total of 12 fields per mouse. Statistics were performed by nonparametric ANOVA using Fisher's least significant difference. Interductal vessels were considered to be normal vasculature and were therefore excluded from analysis.
Constructs and stable cell lines
Stable TRAMP-C2N.iFGFR1 cells were generated by transfection of linearized pEF1-iFGFR1-IRES-Neo into TRAMP-C2N cells followed by selection with 0.4 mg/ml G418. The pEF1-iFGFR1-IRES-Neo construct was made by excising the iFGFR1 gene from pMMP-iFGFR1 (Welm et al., 2002) with NcoI and NotI and ligating into similarly digested pEF1-Luc-IRES-Neo, which was originally made by excising the XhoIXbaI fragment of the firefly luciferase gene from pGL3-Basic (Promega, Madison, WI, USA) and ligating into similarly digested pEF1-IRES-N (Hobbs et al., 1998) . To generate HA-FGFR1, mouse prostate cells derived from the TRAMP model were harvested using Trizol (Invitrogen, Carlsbad, CA, USA) to isolate total RNA. Using Superscript III reverse transcriptase (Invitrogen) and oligo (dT) primers, cDNA was generated to use as a template for PCR. The full-length iiica isoform of FGFR1 was amplified using forward primer 5 0 -CC CAAGCTTCCACCATGGGATACCCTTATGATGTGCCG GATTATGCCTGGGGCTGGAAGTGCCTCCTC-3 0 containing a HindIII restriction site and the HA epitope tag sequence, and reverse primer 5 0 -GCTCTAGATCAGCGCCGTTTGA GTCCACTGTTGGC-3 0 containing a XbaI restriction site. Following gel purification, the PCR product was digested with HindIII and XbaI, and ligated into the multiple cloning site of the pcDNA3.1( þ ) vector (Invitrogen). To generate the Ang-2 luciferase reporter, genomic tail DNA from a wild-type FVB/N mouse was used as a template for PCR. An approximately 3 kb fragment of the Ang-2 promoter region was amplified using forward primer 5 0 -CGACGCGTTAGTGGCAATCA GTGTCCATTGGC-3 0 containing a MluI restriction site, and reverse primer 5 0 -CTAGCTAGCGAGTCTACAGTGTCAG TATCCG-3 0 containing a NheI restriction site. Following gel purification and digestion with MluI and NheI, the Ang-2 promoter fragment was ligated into the pGL3-Basic vector (Promega) that contains the firefly luciferase gene. All clones were confirmed by sequencing conducted at the shared resources of the Fred Hutchinson Cancer Research Center (Seattle, WA, USA).
Luciferase assays COS-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, and transfected using FuGENE 6 transfection reagent (Roche) according to manufacturer's instructions. Approximately 12 h after transfection, cells were washed with PBS and media was replaced with serum-free DMEM. After 24 h in serum-free media, cells were treated where applicable with 20 ng/ml recombinant basic FGF (#100-18B, PeproTech, Rocky Hill, NJ, USA) dissolved in PBS, 100 nM PD173074 (generous gift from W. Klohs and M. Gieseg, Pfizer, Groton, CT, USA) dissolved in DMSO, or DMSO alone, and harvested 2 h later. The Dual Luciferase Reporter assay system (Promega) was used according to manufacturer's instructions and samples were analysed using a LB96V microplate luminometer (Berthold, Oak Ridge, TN, USA).
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